Hydroxychloroquine for IgA nephropathy
Treatments studied
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether hydroxychloroquine can help slow kidney damage in people with IgA nephropathy. You may qualify if you have this kidney disease, are already on two standard medicines (RAAS inhibitors and SGLT2 inhibitors), and have ongoing protein in your urine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have IgA nephropathy confirmed by a kidney biopsy (any time in the past)
- Your last kidney biopsy showed at least one sign of active damage
- Your urine protein level is high (albumin/creatinine ratio over 300 mg/g)
- You are already taking two kidney-protecting medicines (RAAS blocker and SGLT2 inhibitor) for at least 1–3 months
- You are not pregnant or breastfeeding, and you and your partner will use effective birth control if needed
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called CM313 for people with IgA nephropathy, a kidney disease. The goal is to see if it can help reduce protein in the urine and protect kidney function.
This trial tests a new medicine called BHV-1400 for adults with IgA nephropathy, a kidney disease that can cause protein in the urine and kidney damage. The goal is to see if it's safe and effective in slowing the disease.
This trial tests a new pill called finerenone to see if it can slow down kidney damage in people with IgA nephropathy, a type of kidney inflammation. If you qualify, you might get finerenone or a placebo, and the study will monitor your kidney health over time.
This trial is testing if adding another approved drug to standard treatment can slow kidney function decline in people with IgA nephropathy. It aims to find better options for South Asian adults with this condition.
This trial tests a new medication for IgA nephropathy, a kidney disease that causes inflammation and protein loss in urine. It aims to see if the drug can safely slow down kidney damage and protect kidney function.
This phase 3 trial tests an experimental drug (HRS-5965) for people with IgA nephropathy (a kidney disease). It aims to find out if the drug can help reduce protein in the urine and protect kidney function. To join, you must have had a kidney biopsy showing IgA nephropathy within the past 8 years and have significant protein in your urine despite taking standard treatments.
Hear when a new IgA Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.